m bo quyn li, khch hng nn kim tra ha n v tem chng hng gi khi nhn hng
Dosing every 23 weeks is appropriate only during maintenance phases after initial weight loss has plateaued
Common adverse effects of GLP-1 receptor agonists include: Gastrointestinal symptoms (nausea, vomiting, diarrhoea, constipation) Injection site reactions Headache Fatigue Dizziness Important safety considerations include: Risk of hypoglycaemia when used with insulin or sulfonylureas (dose reduction of these agents may be needed) Potential worsening of diabetic retinopathy with semaglutide in patients with pre-existing retinopathy Risk of dehydration and acute kidney injury from persistent vomiting or diarrhoea Pancreatitis, gallbladder disease, and potential thyroid C-cell tumours (observed in rodent studies, though human relevance remains uncertain) Patients should be counselled about persistent severe abdominal pain as a potential warning sign of pancreatitis requiring immediate medical attention
Administration timing may affect blood sugar control and overall tolerance
Funding This research was funded by the National Council of Science and Technology (CONACYT Ciencia Bsica grant number A1-S-8774) and the Universidad de Guadalajara through Fortalecimiento de la Investigacin y el Posgrado 2020
Peptides should be stored in a cool, dry place away from direct sunlight
